Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
about
Molecular-targeted therapy for advanced gastric cancerMolecular-targeted first-line therapy for advanced gastric cancerRecent developments in esophageal adenocarcinomaThe efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials.Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis.miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expressionTumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.HER2 as a target in invasive urothelial carcinoma.Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer.Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country.Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression.Advanced gastric cancer: is there enough evidence to call second-line therapy standard?miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells.Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population.Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma.FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre studyTherapeutic application of monoclonal antibodies in cancer: advances and challenges.Trastuzumab: a review of its use in HER2-positive advanced gastric cancer.Role of Forkhead Box Class O proteins in cancer progression and metastasis.Pertuzumab in gastrointestinal cancer.Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2.HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.A polymorphism site in the pre‑miR‑34a coding region reduces miR‑34a expression and promotes osteosarcoma cell proliferation and migration.Diagnostic pathology of early systemic cancer: ERBB2 gene amplification in single disseminated cancer cells determines patient survival in operable esophageal cancer.Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis.Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients.IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status.Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population
P2860
Q24187006-91BDC6D9-AABC-4008-B726-5E7D34443804Q26471049-EAFC6F97-938F-47E8-9B0E-B65BDC543772Q26849652-EBB59770-7703-4E62-BCD7-6C994E899B53Q33437413-8E144869-4DE1-4AA0-863E-1E3F734F79AEQ33631305-4FE3CC4B-F7A6-40DE-99CD-EB6451633E0AQ33706171-495F4BCD-57FC-4064-BFFA-A46F6AF562DAQ34324683-32C0AA5E-B861-45E5-86EC-69DFBEFB3AAFQ35755382-BC88CF44-0967-45FC-A0CF-4526E7140C6CQ35915145-09C0E79D-4141-420C-A6D4-BE54B8364933Q36184699-FA50873C-DFA1-408B-A347-E1B27847BD20Q36287390-DFE2DFBC-D257-4F74-B077-93B6CF150172Q36429808-6C3EAE4F-AB3A-4414-A212-A5593787C257Q36658350-EB7E98C8-4EF7-49D0-9FE9-7055456F9982Q36897947-A9B2F35A-5291-4F45-A7CA-D1B0CA4D5D61Q37438701-DCA37B1E-53C6-4DAC-97EF-F8B4F88D9370Q37594375-74128CB7-442D-40AF-8E11-AFD3FCF752EEQ38057179-8A32DDFF-32EB-4E9E-976C-563C2381E3EEQ38140697-A22B358B-2985-4B22-8EB5-F66720B6E3D1Q38647185-7A98BB8D-C13F-41AF-BE91-899F6D024287Q38653309-47B07183-6195-495F-ADA7-12DEA9D31A47Q38792755-A512C648-461F-44CE-9629-DADCD5731B64Q39080349-DC772F51-3E67-4A64-9D0D-DF34627733BCQ39400428-AEE8B655-144F-4144-9216-290C15562E0BQ41871223-6D09C3B9-AB99-43D1-B0D8-99F78A7FAEEAQ47770012-DB8894DF-B469-41B5-95AE-D51A8E8D3E28Q48124426-521476EE-BB45-4FF0-8C6A-02DF25DC82DCQ53232564-65303028-6C2D-48EC-9AB0-A0E418B62419Q54314944-88A40067-0A3A-4070-90B4-1045CA33F34DQ58774120-8A38E944-6F23-46A0-8E02-FBE3F93D31EF
P2860
Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Advances in the management of ...... troesophageal junction cancer.
@en
type
label
Advances in the management of ...... troesophageal junction cancer.
@en
prefLabel
Advances in the management of ...... troesophageal junction cancer.
@en
P1476
Advances in the management of ...... troesophageal junction cancer.
@en
P2093
Yung-Jue Bang
P304
P356
10.1097/MCG.0B013E3182557307
P577
2012-09-01T00:00:00Z